Figure 7.

Protective effects of WIN55,212-2 and AM1710 on paclitaxel-induced cold allodynia following drug removal. a. WIN55,212-2 (0.5 and 0.1 mg/kg/day s.c.) suppressed paclitaxel-induced cold allodynia for 12 and 18 days (until day 33 and 39, respectively) following cessation of drug delivery. b. AM1710 (3.2 mg/kg/day s.c.) suppressed cold allodynia for 18 days following drug removal (until day 39). c. AM1710 (3.2 mg/kg/day s.c.) produced a longer duration of protection against cold allodynia compared to WIN55,212-2 (0.5 mg/kg/day s.c.). *P < 0.05, **P < 0.01, ***P <0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P <0.01, ###P <0.001 vs. Taxol-Vehicle, P < 0.05, ⟂⟂P < 0.01 Taxol-Agonist (both doses) vs. Taxol-Vehicle, ϕP < 0.05, ϕϕP <0.01, ϕϕϕP <0.001 Taxol-AM1710 (3.2 mg/kg/day s.c.) and Taxol-WIN-55,212-2 (0.5 mg/kg/day s.c.) vs. Taxol-Vehicle (ANOVA; Dunnett and Tukey post-hoc tests). N = 4–8 per group.

Rahn et al. Molecular Pain 2014 10:27   doi:10.1186/1744-8069-10-27
Download authors' original image